Compare FT & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FT | NGEN |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.8M | 175.1M |
| IPO Year | N/A | N/A |
| Metric | FT | NGEN |
|---|---|---|
| Price | $7.97 | $1.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 46.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.43 | $1.91 |
| 52 Week High | $8.35 | $5.93 |
| Indicator | FT | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.14 | 22.21 |
| Support Level | $7.82 | N/A |
| Resistance Level | $8.05 | $4.52 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.00 | -0.13 |
| Stochastic Oscillator | 44.68 | 1.00 |
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.